Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Tuberculosis

  Free Subscription


13.02.2017

1 Ann Intern Med
1 Antimicrob Agents Chemother
1 Clin Infect Dis
5 Eur Respir J
1 Infect Immun
17 Int J Tuberc Lung Dis
1 Lancet
2 Lancet Respir Med
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Intern Med

  1. JACOBSON KR
    Tuberculosis.
    Ann Intern Med. 2017;166:ITC17-ITC32.
    PubMed     Text format     Abstract available


    Antimicrob Agents Chemother

  2. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
    Acquisition of rifampin resistance in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  3. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed     Text format    


    Eur Respir J

  4. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Text format     Abstract available

  5. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed     Text format    

  6. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed     Text format    

  7. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Text format     Abstract available

  8. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed     Text format    


    Infect Immun

  9. ANURADHA R, Munisankar S, Bhootra Y, Dolla C, et al
    Anthelmintic therapy modifies the systemic and mycobacterial-antigen-stimulated cytokine profile in helminth-latent Mycobacterium tuberculosis co-infection.
    Infect Immun. 2017 Feb 6. pii: IAI.00973-16. doi: 10.1128/IAI.00973.
    PubMed     Text format     Abstract available


    Int J Tuberc Lung Dis

  10. CHABALA C, Chongwe G, Jumbe-Marsden E, Somwe SW, et al
    Missed opportunities for screening child contacts of smear-positive tuberculosis in Zambia, a high-prevalence setting.
    Int J Tuberc Lung Dis. 2017;21:53-59.
    PubMed     Text format     Abstract available

  11. EGERE U, Togun T, Sillah A, Mendy F, et al
    Identifying children with tuberculosis among household contacts in The Gambia.
    Int J Tuberc Lung Dis. 2017;21:46-52.
    PubMed     Text format     Abstract available

  12. ZELDOW B, Kim S, McSherry G, Cotton MF, et al
    Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.
    Int J Tuberc Lung Dis. 2017;21:38-45.
    PubMed     Text format     Abstract available

  13. JERENE D, Abebe W, Taye K, Suarez PG, et al
    Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.
    Int J Tuberc Lung Dis. 2017;21:32-37.
    PubMed     Text format     Abstract available

  14. TUPASI T, Garfin AM, Mangan JM, Orillaza-Chi R, et al
    Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up.
    Int J Tuberc Lung Dis. 2017;21:23-31.
    PubMed     Text format     Abstract available

  15. WELDEGEBREAL S, Mebrahtu T
    Anti-tuberculosis drug resistance in Ethiopia: systematic review.
    Int J Tuberc Lung Dis. 2017;21:18-22.
    PubMed     Text format     Abstract available

  16. KOURA KG, Trebucq A, Schwoebel V
    Do active case-finding projects increase the number of tuberculosis cases notified at national level?
    Int J Tuberc Lung Dis. 2017;21:73-78.
    PubMed     Text format     Abstract available

  17. BANU S, Rahman MT, Ahmed S, Khatun R, et al
    Multidrug-resistant tuberculosis in Bangladesh: results from a sentinel surveillance system.
    Int J Tuberc Lung Dis. 2017;21:12-17.
    PubMed     Text format     Abstract available

  18. RAGONNET R, Trauer JM, McBryde ES, Houben RM, et al
    Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact.
    Int J Tuberc Lung Dis. 2017;21:60-66.
    PubMed     Text format     Abstract available

  19. RUDOLF F, Wagner AJ, Back FM, Gomes VF, et al
    Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR.
    Int J Tuberc Lung Dis. 2017;21:67-72.
    PubMed     Text format     Abstract available

  20. FURIN J, Diacon AH, Andries K
    Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Int J Tuberc Lung Dis. 2017;21:4-5.
    PubMed     Text format    

  21. SHAWENO D, Shaweno T, Trauer JM, Denholm JT, et al
    Heterogeneity of distribution of tuberculosis in Sheka Zone, Ethiopia: drivers and temporal trends.
    Int J Tuberc Lung Dis. 2017;21:79-85.
    PubMed     Text format     Abstract available

  22. DAVIS A, Terlikbayeva A, Aifah A, Hermosilla S, et al
    Risks for tuberculosis in Kazakhstan: implications for prevention.
    Int J Tuberc Lung Dis. 2017;21:86-92.
    PubMed     Text format     Abstract available

  23. KUMAR NP, Velayutham B, Nair D, Babu S, et al
    Angiopoietins as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis.
    Int J Tuberc Lung Dis. 2017;21:93-99.
    PubMed     Text format     Abstract available

  24. REVES R, Benjamin R
    The cost of the failure to eliminate tuberculosis in the United States.
    Int J Tuberc Lung Dis. 2017;21:120.
    PubMed     Text format    

  25. RIEDER HL, Van Deun A
    Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.
    Int J Tuberc Lung Dis. 2017;21:123-124.
    PubMed     Text format    

  26. NOURZAD S, Jenkins HE, Milstein M, Mitnick CD, et al
    Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.
    Int J Tuberc Lung Dis. 2017;21:6-11.
    PubMed     Text format     Abstract available


    Lancet

  27. COUSINS S
    Myanmar grapples with its high tuberculosis burden.
    Lancet. 2017;389:491-492.
    PubMed     Text format    


    Lancet Respir Med

  28. RUHWALD M, Aggerbeck H, Gallardo RV, Hoff ST, et al
    Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.
    Lancet Respir Med. 2017 Jan 31. pii: S2213-2600(16)30436.
    PubMed     Text format     Abstract available

  29. ABUBAKAR I, Jackson C, Rangaka MX
    C-Tb: a latent tuberculosis skin test for the 21st century?
    Lancet Respir Med. 2017 Jan 31. pii: S2213-2600(17)30012.
    PubMed     Text format    


    PLoS One

  30. ALENE KA, Viney K, McBryde ES, Clements AC, et al
    Spatial patterns of multidrug resistant tuberculosis and relationships to socio-economic, demographic and household factors in northwest Ethiopia.
    PLoS One. 2017;12:e0171800.
    PubMed     Text format     Abstract available

  31. REYNAUD Y, Zheng C, Wu G, Sun Q, et al
    Bayesian population structure analysis reveals presence of phylogeographically specific sublineages within previously ill-defined T group of Mycobacterium tuberculosis.
    PLoS One. 2017;12:e0171584.
    PubMed     Text format     Abstract available

  32. HUNDIE GB, Woldemeskel D, Gessesse A
    Correction: Evaluation of Direct Colorimetric MTT Assay for Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis.
    PLoS One. 2017;12:e0171964.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: